Kookjeon Pharmaceutical Co (307750) Fair Value & Analysis
Healthcare · KR · Market cap 124B KRW
Fair value as of: Jun 24, 2026
Analysis
Kookjeon Pharmaceutical Co (307750) currently trades at 2,090 KRW, while our model-based Fair Value estimate is 3,455 KRW — implying the stock looks roughly 65.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Kookjeon Pharmaceutical Co., Ltd. operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic materials, such as antistatic agents, monomers and polymers with low dielectric constant, and UV curing agents; low-resistance electrolyte, phosphine, silane, and boron compounds; semiconductor materials; and carbazole, boric acid, and fluorene intermediates. In addition, the company owns patents for its manufacturing methods. It serves pharmaceuticals, intermediate products, new drug synthesis, and related materials industries. The company was founded in 1972 and is headquartered in Anyang-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Kookjeon Pharmaceutical Co (307750) undervalued?
What is the fair value of 307750?
What is the quality score of 307750?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.